Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Faron Pharmaceuticals Oy has granted 100,000 options for new ordinary shares under its 2019 Share Option Plan, with an exercise period between 2025 and 2028 and a strike price of €1.48 per share. These options represent a modest 0.1% of the company’s fully diluted share capital and are part of a strategy to incentivize management, including a grant to top executive Petri Bono. The company is actively engaged in cancer immunotherapy research, with its lead asset bexmarilimab currently in phase I/II clinical trials for hematological cancers.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.